Background: Pulmonary tuberculosis (PTB) is the main apprehension universally. Although treatable, tuberculosis (TB) endures depressingly and disturbs patients’ health-related quality of life (HRQoL) and functioning even after treatment.1 Resources have revealed that multidrug treatments can lead to unwanted adversative drug reactions such as arthralgia, neurological disorders, hepatotoxicity, and allergic reactions. TB affects the respiratory system, that is, airflow patterns, functional exercise capacity, and ultimately the QoL of patients even after the completion of the 4-month rifapentine-moxifloxacin TB treatment regimen and 6- or 9-month rifapentine, isoniazid, pyrazinamide, and ethambutol (RIPE) TB treatment regimen. Throughout the treatment of active PBT, lung function damage is usually restrictive. Materials and methods: A total of 86 PTB survivors were selected for the PTB survivors’ group, who had a history of taking complete treatment for PTB. Each survivor was evaluated for functional exercise capacity with a 12-minute walk test (MWT), 15-step oximetry test, and HRQoL questionnaire. Results: Pulmonary tuberculosis (PTB) causes variation in vitals and also has negative effects on physical functioning. The study results demonstrated that out of 86 total respondents, the majority (97–100%) had better oxygen levels pretest (12-MWT and pulse oximetry) with an average of 17–20 bpm. 47% of individuals were underweight, with posttest oxygen saturation reduced to 91–93% and respiratory rate increased to 26–30 bpm. QoL was also compromised. Conclusion: This present study concluded that PTBs and their treatment do affect the functional exercise capacity of the survivors. The respiratory rate and blood pressure are markedly increased, whereas the oxygen saturation and manual muscle strength are markedly reduced. PTB survivors also suffered from compromised health and QoL, that is, emotional and mental weaknesses.
Daniels KJ, Irusen E, Pharaoh H, et al. Post-tuberculosis health-related quality of life, lung function and exercise capacity in a cured pulmonary tuberculosis population in the Breede Valley District, South Africa. S Afr J Physiother 2019;75(1):1319. DOI: 10.4102/sajp.v75i1.1319
Tuberculosis, 14th October 2021. World Health Organisation, https://www.who.int/news-room/fact-sheets/detail/tuberculosis
Ozdemir M, Ozdemir HG. Evaluation of patients admitted with musculoskeletal tuberculosis: sixteen years’ experience from a single center in Turkey. BMC Musculoskelet Disord 2021;22(1):542. DOI: 10.1186/s12891-021-04426-y
Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2020;24(7):700–705. DOI: 10.5588/ijtld.19.0809
Farazi A, Sofian M, Jabbariasl M, et al. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014;2014:412893. DOI: 10.1155/2014/412893
Gülbay BE, Gürkan OU, Yildiz OA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006;100(10):1834–1842. DOI: 10.1016/j.rmed.2006.01.014
Singla R, Sharma SK, Mohan A, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010;132:81–86.
Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007;(4):CD003343. DOI: 10.1002/14651858.CD003343.pub3
Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007;11(8):868–875.
Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ 2008;86(3):B–D. DOI: 10.2471/blt.07.043802
Kaona FA, Tuba M, Siziya S, et al. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 2004;4(1):68. DOI: 10.1186/1471-2458-4-68
Javadi MR, Shalviri G, Gholami K, et al. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf 2007;16(10):1104–1110. DOI: 10.1002/pds.1468
McKnight-Eily LR, Okoro CA, Strine TW, et al. Racial and ethnic disparities in the prevalence of stress and worry, mental health conditions, and increased substance use among adults during the COVID-19 pandemic—United States, April and May 2020. MMWR Morb Mortal Wkly Rep 2021;70(5):162–166. DOI: 10.15585/mmwr.mm7005a3
Okoro CA, Strine TW, McKnight-Eily L, et al. Indicators of poor mental health and stressors during the COVID-19 pandemic, by disability status: a cross-sectional analysis. Disabil Health J 2021;14(4):101110. DOI: 10.1016/j.dhjo.2021.101110
Gupta N, Bhatnagar AK. Musculoskeletal manifestations of tuberculosis: an observational study. J Family Med Prim Care 2018;7(3):538–541. DOI: 10.4103/jfmpc.jfmpc_7_17
Jadhav AR, Shinde SB. Functional exercise capacity in young survivors of acute respiratory distress syndrome. Indian J Tuberc 2020;67(2):163–166. DOI: 10.1016/j.ijtb.2019.08.008
Samuel R, Natesan S, Bangera MK. Quality of life and associating factors in pulmonary tuberculosis patients. Indian J Tuberc 2022. DOI: 10.1016/j.ijtb.2022.05.005